Six late-breaking clinical trials have been accepted for presentation next week during the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition in Denver, CO. These trials were selected based upon their potential impact to the field of nephrology.
The trials will be presented on Saturday, November 20 in the Wells Fargo Theater of the Colorado Convention Center from 10:30 am - 12:30 pm MT in the following order:
- Effects of Nocturnal Home Hemodialysis: The Frequent Hemodialysis Network (FHN) Trials
- Effect of Bardoxolone Methyl on Renal Function in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus
- Results of the Multicenter FSGS Clinical Trial in Children and Young Adults
- Primary Safety and Efficacy Results from Four Phase 3 Randomized, Active-controlled, Open-label Studies of Hematide/Peginesatide among CKD Dialysis and Nondialysis Patients
- Prevention of Dialysis Catheter Lumen Occlusion with RT-PA versus Heparin (Preclot): A Randomized Trial
- Should We Reduce LDL Cholesterol in Patients with Chronic Kidney Disease? The Results of the Study of Heart and Renal Protection (SHARP)
These presentations will also be presented at a press briefing on Saturday, November 20 from 9:15 am - 10:15 am MT in Room 208 of the Colorado Convention Center.
New research identifies potential drug target to prevent kidney failure